CRISPR Q2 net loss $185.8M; exa-cel on track for EU/UK regulatory filing by year-end

CRISPR Therapeutics AG

2022-Q2 EPS reported -$4.72 revenue$1,098,000

Net loss of $185.8M in Q2 2022 vs net income of $759.2M in Q2 2021; revenue fell to $0.2M from $900.2M due to prior-year Vertex upfront.
Cash & equivalents $2.07B as of June 30, 2022 (down from $2.38B at Dec 31, 2021); cash used for R&D and pre-commercial costs.
exa-cel: CLIMB-111/121 fully enrolled; regulatory submissions for SCD & TDT planned in Europe/UK by end of 2022; FDA discussions ongoing.
Enrollment continuing for CTX110 (CD19+), CTX130 (CD70) in solid/hematologic tumors; CTX110 data expected in 2022.
Next-gen CAR-T INDs (CTX131, CTX112) expected by year-end; VCTX211 CTA for T1D in H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.